These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 18083294)

  • 1. Validation of the contemporary epstein criteria for insignificant prostate cancer in European men.
    Jeldres C; Suardi N; Walz J; Hutterer GC; Ahyai S; Lattouf JB; Haese A; Graefen M; Erbersdobler A; Heinzer H; Huland H; Karakiewicz PI
    Eur Urol; 2008 Dec; 54(6):1306-13. PubMed ID: 18083294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of the Epstein criteria for prediction of clinically insignificant prostate cancer in Korean men.
    Lee SE; Kim DS; Lee WK; Park HZ; Lee CJ; Doo SH; Jeong SJ; Yoon CY; Byun SS; Choe G; Hwang SI; Lee HJ; Hong SK
    BJU Int; 2010 Jun; 105(11):1526-30. PubMed ID: 19912202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of pathological prostate cancer characteristics in men with favorable biopsy features on predominantly sextant biopsy.
    Chun FK; Suardi N; Capitanio U; Jeldres C; Ahyai S; Graefen M; Haese A; Steuber T; Erbersdobler A; Montorsi F; Huland H; Karakiewicz PI
    Eur Urol; 2009 Mar; 55(3):617-28-6. PubMed ID: 18499335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of insignificant clinical T1c prostate tumors. A contemporary analysis.
    Bastian PJ; Mangold LA; Epstein JI; Partin AW
    Cancer; 2004 Nov; 101(9):2001-5. PubMed ID: 15372478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men.
    Chun FK; Haese A; Ahyai SA; Walz J; Suardi N; Capitanio U; Graefen M; Erbersdobler A; Huland H; Karakiewicz PI
    Cancer; 2008 Aug; 113(4):701-9. PubMed ID: 18553365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of biochemical recurrence rate in patients with pathologically confirmed insignificant prostate cancer.
    Capitanio U; Ahyai S; Graefen M; Jeldres C; Shariat SF; Erbersdobler A; Schlomm T; Haese A; Steuber T; Heinzer H; Perrotte P; Péloquin F; Pharand D; Arjane P; Huland H; Karakiewicz PI
    Urology; 2008 Dec; 72(6):1208-11; discussion 1212-3. PubMed ID: 18692880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancer.
    Loeb S; Roehl KA; Thaxton CS; Catalona WJ
    Urology; 2008 Jul; 72(1):143-7. PubMed ID: 18436287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
    BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Currently used criteria for active surveillance in men with low-risk prostate cancer: an analysis of pathologic features.
    Suardi N; Capitanio U; Chun FK; Graefen M; Perrotte P; Schlomm T; Haese A; Huland H; Erbersdobler A; Montorsi F; Karakiewicz PI
    Cancer; 2008 Oct; 113(8):2068-72. PubMed ID: 18792067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The contemporary concept of significant versus insignificant prostate cancer.
    Ploussard G; Epstein JI; Montironi R; Carroll PR; Wirth M; Grimm MO; Bjartell AS; Montorsi F; Freedland SJ; Erbersdobler A; van der Kwast TH
    Eur Urol; 2011 Aug; 60(2):291-303. PubMed ID: 21601982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
    Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
    Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness.
    Loeb S; Sutherland DE; D'Amico AV; Roehl KA; Catalona WJ
    Urology; 2008 Nov; 72(5):1116-20; discussion 1120. PubMed ID: 18571700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Editorial comment on: validation of the contemporary epstein criteria for insignificant prostate cancer in European men.
    Lopez-Beltran A; Montironi R
    Eur Urol; 2008 Dec; 54(6):1311-2. PubMed ID: 18083295
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial comment on: validation of the contemporary Epstein criteria for insignificant prostate cancer in European men.
    Salonia A
    Eur Urol; 2008 Dec; 54(6):1312-3. PubMed ID: 18083297
    [No Abstract]   [Full Text] [Related]  

  • 15. A pathological reassessment of organ-confined, Gleason score 6 prostatic adenocarcinomas that progress after radical prostatectomy.
    Miyamoto H; Hernandez DJ; Epstein JI
    Hum Pathol; 2009 Dec; 40(12):1693-8. PubMed ID: 19683331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is quantitative histologic examination useful to predict nonorgan-confined prostate cancer when saturation biopsy is performed?
    Pepe P; Fraggetta F; Galia A; Grasso G; Piccolo S; Aragona F
    Urology; 2008 Dec; 72(6):1198-202. PubMed ID: 19041023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice.
    Dong F; Kattan MW; Steyerberg EW; Jones JS; Stephenson AJ; Schröder FH; Klein EA
    J Urol; 2008 Jul; 180(1):150-4; discussion 154. PubMed ID: 18485398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer.
    Naito S; Kuroiwa K; Kinukawa N; Goto K; Koga H; Ogawa O; Murai M; Shiraishi T;
    J Urol; 2008 Sep; 180(3):904-9; discussion 909-10. PubMed ID: 18635221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy.
    Ward JF; Nakanishi H; Pisters L; Babaian RJ; Troncoso P
    BJU Int; 2009 Aug; 104(4):490-7. PubMed ID: 19220260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection.
    Briganti A; Karakiewicz PI; Chun FK; Suardi N; Gallina A; Abdollah F; Freschi M; Doglioni C; Rigatti P; Montorsi F
    Int J Urol; 2009 Aug; 16(8):676-81. PubMed ID: 19602006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.